HCC Clinical Trials

37 recruiting

HCC Trials at a Glance

179 actively recruiting trials for hcc are listed on ClinicalTrialsFinder across 6 cities in 32 countries. The largest study group is Phase 2 with 68 trials, with the heaviest enrollment activity in Shanghai, Guangzhou, and Hong Kong. Lead sponsors running hcc studies include Fudan University, IRCCS Azienda Ospedaliero-Universitaria di Bologna, and Chang Gung Memorial Hospital.

Treatments under study

About HCC Clinical Trials

Looking for clinical trials for HCC? There are currently 37 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new HCC trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about HCC clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 179 trials

Recruiting
Phase 1

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Endometrial CancerRenal Cell Carcinoma (RCC)Hepatocellular Carcinoma (HCC)+1 more
Compass Therapeutics70 enrolled3 locationsNCT07419841
Recruiting
Phase 2

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

Hepatocellular CarcinomaHCC
University of California, Irvine35 enrolled1 locationNCT04472767
Recruiting
Phase 2

Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma

HCC - Hepatocellular CarcinomaConversion Therapy
Tianjin Medical University Cancer Institute and Hospital43 enrolled1 locationNCT07560488
Recruiting
Phase 2

SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin

Hepato Cellular Carcinoma (HCC)Hand Foot Skin Syndrome
National Taiwan University Hospital39 enrolled1 locationNCT07560566
Recruiting
Not Applicable

Computer Guided Microwave Liver Ablation

Hepatocellular Carcinoma (HCC)
NE Scientific INC84 enrolled2 locationsNCT07226869
Recruiting
Phase 3

DEB-TACE vs cTACE in HCC After TIPS

Hepatocellular Carcinoma (HCC)TACETIPS+2 more
First Affiliated Hospital, Sun Yat-Sen University206 enrolled1 locationNCT07322848
Recruiting
Phase 1

Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer

Hepatocellular Carcinoma (HCC)
University of Hawaii15 enrolled2 locationsNCT07075120
Recruiting
Phase 2

A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC

Hepatocellular Carcinoma (HCC)
Second Affiliated Hospital, School of Medicine, Zhejiang University36 enrolled1 locationNCT07422753
Recruiting

Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment

Advanced Hepatocellular Carcinoma (HCC)
Fudan University150 enrolled1 locationNCT07147101
Recruiting
Phase 2

A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma

Hepato Cellular Carcinoma (HCC)
Fudan University350 enrolled1 locationNCT07328009
Recruiting
Phase 2

HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)

Hepatocellular Carcinoma (HCC)
Fudan University164 enrolled1 locationNCT06860490
Recruiting
Phase 2

A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC

HCC - Hepatocellular Carcinoma
TaiRx, Inc.40 enrolled1 locationNCT07521852
Recruiting
Phase 2

Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma

Hepato Cellular Carcinoma (HCC)
Fudan University40 enrolled1 locationNCT07536789
Recruiting
Phase 2Phase 3

A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.

Hepatocellular Carcinoma (HCC)
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.680 enrolled2 locationsNCT07490262
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

Hepatocellular Carcinoma (HCC)
Bristol-Myers Squibb129 enrolled46 locationsNCT07291076
Recruiting
Not Applicable

Scout Dose of Resin Microspheres

Hepatocellular Carcinoma (HCC)Radioembolization
Seoul National University Hospital30 enrolled1 locationNCT07476651
Recruiting

AI-Assisted Staging and Treatment Decision-Making for Hepatocellular Carcinoma

Hepatocellular Carcinoma (HCC)
Beijing Tsinghua Chang Gung Hospital108 enrolled1 locationNCT07538882
Recruiting
Not Applicable

Electronic Symptom Monitoring of Patient-Reported Outcomes Among Patients With Hepatocellular Carcinoma During Immunotherapy (PRIME-HCC): Protocol for a Randomised Controlled Trial

Hepatocellular Carcinoma (HCC)
Wei Xiaoping500 enrolled1 locationNCT06938945
Recruiting
Phase 1Phase 2

Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC

Hepatocellular Carcinoma (HCC)
RayzeBio, Inc.590 enrolled13 locationsNCT06726161
Recruiting

Same-day Radioembolization for Large HCC

Hepatocellular Carcinoma (HCC)
Seoul National University Hospital138 enrolled4 locationsNCT06944483